Psyence Biomedical Ltd. PBM
Psyence Biomedical Ltd. (Nasdaq: PBM) is a CNS/neurology/psychiatry drug developer. Its lead program, NPX-5 (nature-derived psilocybin 25 mg), is in Phase 2 for Adjustment disorder in patients with incurable cancer (palliative care). Its next catalyst on record is ibogaine: Psyence expects to conclude definitive agreement with PsyLabs for exclusive ibogaine supply for the United States on or before November 30, 2026. (November 2026).
Upcoming catalysts
- November 2026ibogaine — Psyence expects to conclude definitive agreement with PsyLabs for exclusive ibogaine supply for the United States on or before November 30, 2026.
PsyLabs is expected to serve as TIRC's exclusive ibogaine supplier for the United States, subject to the conclusion of a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NPX-5 | Adjustment disorder due to incurable cancer (Phase IIb, Australia, 87 patients) | small molecule | Phase 2 |
| Nature-derived psilocybin (PsyLabs API) | Alcohol use disorder and other substance use disorders | small molecule | Pre-clinical |
| Nature-derived ibogaine (right of first refusal) | Substance use disorders | small molecule | Pre-clinical |
Recent results and decisions
- Oct 21, 2026completed Psyence BioMed completes regulatory readiness documentation package for ibogaine intended to support future U.S. regulatory interactions.
PsyLabs has completed its ibogaine regulatory readiness pack, a documentation package intended to support future regulatory interactions relating to pharmaceutical-grade ibogaine hydrochloride (HCl).
Filing - Oct 21, 2026n/a Texas Ibogaine Research Corporation enters manufacturing services agreement with DEA-registered Benuvia for planned U.S. cGMP manufacture of pharmaceutical-grade ibogaine API.
A manufacturing services agreement has been entered into with Benuvia by Texas Ibogaine Research Corporation, the Company's wholly-owned Texas subsidiary.
Filing - Oct 21, 2026n/a Psyence BioMed completes additional $2.6 million investment in PsyLabs following achievement of ibogaine milestones, increasing ownership to approximately 43.37%.
Psyence Biomed II Corp. subscribed for 1,014 ordinary shares of PsyLabs at US$2,564 per share, for aggregate subscription proceeds of US$2,599,896.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.